Loading
JPXHealthcareBiotechnology
Latest quote
¥608
¥0.00 · 0.00%
Human Metabolome Technologies, Inc. is a biotechnology company based in Tsuruoka, Japan, established in 2003. It focuses on developing and providing metabolomics technologies and solutions for a range of applications, including drug discovery, disease diagnosis, and food production primarily within Japan. The company offers a comprehensive suite of metabolome analysis services, encompassing global profiling, targeted assays, flux analysis, and lipidomics. Additionally, it develops biomarkers, such as Phosphorylethanolamine, which is measured in blood plasma as a marker for major depressive disorder. HMT's solutions address diverse areas like cancer metabolism, infectious diseases, basic and clinical research, food and nutrition, and microbiome studies. The company also fosters collaborations, notably with the Institute for Advanced Biosciences and Keio University, to further advance metabolome analysis technology.
Latest quote
¥608
¥0.00 · 0.00%
Regular session · JST · Market data may be delayed.
Human Metabolome Technologies, Inc. is a biotechnology company based in Tsuruoka, Japan, established in 2003. It focuses on developing and providing metabolomics technologies and solutions for a range of applications, including drug discovery, disease diagnosis, and food production primarily within Japan. The company offers a comprehensive suite of metabolome analysis services, encompassing global profiling, targeted assays, flux analysis, and lipidomics. Additionally, it develops biomarkers, such as Phosphorylethanolamine, which is measured in blood plasma as a marker for major depressive disorder. HMT's solutions address diverse areas like cancer metabolism, infectious diseases, basic and clinical research, food and nutrition, and microbiome studies. The company also fosters collaborations, notably with the Institute for Advanced Biosciences and Keio University, to further advance metabolome analysis technology.
Day range
Current ¥608
52-week range
Current ¥608
Regular session · JST · Market data may be delayed.
Human Metabolome Technologies, Inc. is a biotechnology company based in Tsuruoka, Japan, established in 2003. It focuses on developing and providing metabolomics technologies and solutions for a range of applications, including drug discovery, disease diagnosis, and food production primarily within Japan. The company offers a comprehensive suite of metabolome analysis services, encompassing global profiling, targeted assays, flux analysis, and lipidomics. Additionally, it develops biomarkers, such as Phosphorylethanolamine, which is measured in blood plasma as a marker for major depressive disorder. HMT's solutions address diverse areas like cancer metabolism, infectious diseases, basic and clinical research, food and nutrition, and microbiome studies. The company also fosters collaborations, notably with the Institute for Advanced Biosciences and Keio University, to further advance metabolome analysis technology.
Day range
Current ¥608
52-week range
Current ¥608
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.42B JPY | 1.46B JPY | 1.35B JPY | 1.3B JPY | 1.22B JPY |
| Cost of goods sold | 553.42M JPY | 533M JPY | 476.34M JPY | 439.47M JPY | 383.28M JPY |
| Gross profit | 868.53M JPY | 922M JPY | 869.33M JPY | 859.75M JPY | 840.01M JPY |
| Research and development | — | — | 146M JPY | 185M JPY | 158M JPY |
| Selling, general, and administrative | 658.61M JPY | 672M JPY | 457.91M JPY | 454M JPY | 486M JPY |
| Operating expenses | 658.61M JPY | 673M JPY | 649.16M JPY | 648.77M JPY | 648.85M JPY |
| Interest income | 2.76M JPY | 880K JPY | 14K JPY | 14K JPY | 11K JPY |
| Interest expense | 1.98M JPY | 2.49M JPY | 2.1M JPY | 2.27M JPY | 2.21M JPY |
| Depreciation and amortization | 111.35M JPY | 103M JPY | 86.32M JPY | 80.39M JPY | 64.9M JPY |
| Operating income | 209.91M JPY | 249M JPY | 220.17M JPY | 210.98M JPY | 191.15M JPY |
| Net income | 200.36M JPY | 256M JPY | 243.25M JPY | 285.76M JPY | 267.79M JPY |
Company facts updated Sep 12, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Cash distributions grouped by calendar year; partial years are marked.
¥15.00
2025 complete year+50.0% since 2023
2026 partial: ¥18.00
¥10.00
2,023
¥15.00
2,024
¥15.00
2,025
¥18.00
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
DividendUpcoming | Jun 29, 2027 | ¥18.00Annual | Jun 30, 2027 | Jun 29, 2027 |
Dividend | Jun 29, 2026 | ¥18.00Annual | Jun 30, 2026 | Sep 3, 2026 |
Dividend | Jun 27, 2025 | ¥15.00Annual | Jun 30, 2025 | Sep 4, 2025 |
Dividend | Jun 27, 2024 | ¥15.00Annual | Jun 30, 2024 | Sep 5, 2024 |
Dividend | Jun 29, 2023 | ¥10.00Annual | Jun 30, 2023 | Sep 7, 2023 |
Ex-dividend Jun 29, 2027
¥18.00
Annual
Record Jun 30, 2027 · Payment Jun 29, 2027
Ex-dividend Jun 29, 2026
¥18.00
Annual
Record Jun 30, 2026 · Payment Sep 3, 2026
Ex-dividend Jun 27, 2025
¥15.00
Annual
Record Jun 30, 2025 · Payment Sep 4, 2025
Ex-dividend Jun 27, 2024
¥15.00
Annual
Record Jun 30, 2024 · Payment Sep 5, 2024
Ex-dividend Jun 29, 2023
¥10.00
Annual
Record Jun 30, 2023 · Payment Sep 7, 2023
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
